Artwork

Content provided by BioCentury. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioCentury or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm

30:52
 
Share
 

Manage episode 416017395 series 3571902
Content provided by BioCentury. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioCentury or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.
On the tenth anniversary of a viral media campaign for access to an unapproved drug that extended a boy’s life, bioethicist Arthur Caplan reflected in an interview with The BioCentury Show on how the experience reshaped public views, corporate policies and legal requirements associated with providing access to unapproved therapies.
The wide-ranging conversation also touched on the need for scientists to receive communications training that could help reduce the impacts of medical disinformation, Caplan’s concerns about the lack of transparency about Neuralink Corp.’s experimental implantable brain chip, and the benefits of teaching biopharma CEOs about ethics.
View full story: https://www.biocentury.com/article/651502

#biotech #pharma #biopharma #TheBioCenturyShow
00:00 - Intro
01:12 - Josh Hardy & Compassionate Use
13:27 - Ethics Training for the C-suite
16:16 - FDA
23:44 - Neuralink & Transparency

  continue reading

Chapters

1. Introduction (00:00:00)

2. Josh Hardy & Compassionate Use (00:01:12)

3. Ethics Training for the C-suite (00:13:27)

4. FDA (00:16:15)

5. Neuralink & Transparency (00:23:44)

21 episodes

Artwork
iconShare
 
Manage episode 416017395 series 3571902
Content provided by BioCentury. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioCentury or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.
On the tenth anniversary of a viral media campaign for access to an unapproved drug that extended a boy’s life, bioethicist Arthur Caplan reflected in an interview with The BioCentury Show on how the experience reshaped public views, corporate policies and legal requirements associated with providing access to unapproved therapies.
The wide-ranging conversation also touched on the need for scientists to receive communications training that could help reduce the impacts of medical disinformation, Caplan’s concerns about the lack of transparency about Neuralink Corp.’s experimental implantable brain chip, and the benefits of teaching biopharma CEOs about ethics.
View full story: https://www.biocentury.com/article/651502

#biotech #pharma #biopharma #TheBioCenturyShow
00:00 - Intro
01:12 - Josh Hardy & Compassionate Use
13:27 - Ethics Training for the C-suite
16:16 - FDA
23:44 - Neuralink & Transparency

  continue reading

Chapters

1. Introduction (00:00:00)

2. Josh Hardy & Compassionate Use (00:01:12)

3. Ethics Training for the C-suite (00:13:27)

4. FDA (00:16:15)

5. Neuralink & Transparency (00:23:44)

21 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide